Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions
February 12 2024 - 4:05PM
Business Wire
- Centralized data science platform streamlines clinical study
data management for swift, insight-driven clinical decisions and
therapeutic advancements
- Seamless integration with Spotfire® for powerful visual
analytics enabling flexibility, easy customization and
scalability
- Fosters cross-functional collaboration and improves overall
efficiency in clinical research and development
Today, Revvity, Inc. (NYSE: RVTY) announced that its software
and informatics division, Revvity Signals, is unveiling the Signals
ClinicalTM solution, a software-as-a-service (SaaS), end-to-end
clinical data science platform designed to centralize all clinical
trial data, providing fast, actionable insights for quicker
clinical decisions and accelerated market delivery of therapeutics.
This state-of-the-art solution, when integrated with
enterprise-class Spotfire visual analytics, has the potential to
redefine how the pharmaceutical, biotechnology, and contract
research industries approach clinical trial data, offering an
unprecedented level of access and insight to drive forward clinical
development and therapeutic innovations.
Kevin Willoe, SVP and general manager of Revvity Signals
Software, Inc., emphasized the transformative potential of Signals
Clinical, stating, "In the high-stakes realms of pharma, biotech,
and contract research, the ability to swiftly and safely bring new
treatments to market is paramount. Signals Clinical is our answer
to the industry's urgent need for a solution that not only is
designed to protect patient safety but also empowers data-driven
decision-making with near real-time analytics. By integrating this
platform with advanced data visualization tools, we're enabling our
customers to navigate the complexities of clinical development with
greater ease and efficiency, thereby accelerating the delivery of
new drugs to patients."
Centralizing Clinical Data for Accelerated Decisions
Signals Clinical centralizes all clinical development data in
one location and enables self-service access to clinical trial
data, providing users with a complete picture of patient safety,
treatment efficacy, and trial progress. This centralization enables
rapid, actionable insights, facilitating faster and more informed
clinical decisions, and significantly accelerating the
time-to-market for essential therapeutics.
Empowering Life Sciences with Advanced Analytics
Signals Clinical, when combined with Spotfire not only
streamlines the data preparation process but also enhances the
delivery of strategic analyses, such as safety, efficacy and
cross-study analysis. By reducing the time and resources spent on
manual data handling, Signals Clinical allows organizations to
focus on delivering critical clinical trial insights and fostering
cross-functional collaboration.
Leading with FAIR Practices for Collaborative Data
Management
Championing FAIR principles, the platform streamlines data
preparation, reducing effort and maximizing value. It offers
customizable workflows for data management, clinical review, and
study monitoring, along with integrated collaboration tools. These
features allow queries to be documented and referenced by study
managers, enhancing collaboration and boosting overall team
efficiency for clinical researchers.
Revvity Signals Software will present its Signals Clinical
platform for the first time at the 15th Annual SCOPE conference
(Booth #236), February 11-14, in Orlando, Florida.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is
a call to action. Revvity provides health science solutions,
technologies, expertise and services that deliver complete
workflows from discovery to development, and diagnosis to cure.
Revvity is revolutionizing what’s possible in healthcare, with
specialized focus areas in translational multi-omics technologies,
biomarker identification, imaging, prediction, screening, detection
and diagnosis, informatics and more.
With 2023 revenue of more than $2.7 billion and over 11,000
employees, Revvity serves customers across pharmaceutical and
biotech, diagnostic labs, academia and governments. It is part of
the S&P 500 index and has customers in more than 190
countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube,
Facebook and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240212868098/en/
Investor Relations: Steve Willoughby
steve.willoughby@revvity.com
Media Relations: Chet Murray (781) 663-5719
chet.murray@revvity.com
Revvity (NYSE:RVTY)
Historical Stock Chart
From May 2024 to Jun 2024
Revvity (NYSE:RVTY)
Historical Stock Chart
From Jun 2023 to Jun 2024